JPWO2019246486A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019246486A5
JPWO2019246486A5 JP2020570813A JP2020570813A JPWO2019246486A5 JP WO2019246486 A5 JPWO2019246486 A5 JP WO2019246486A5 JP 2020570813 A JP2020570813 A JP 2020570813A JP 2020570813 A JP2020570813 A JP 2020570813A JP WO2019246486 A5 JPWO2019246486 A5 JP WO2019246486A5
Authority
JP
Japan
Prior art keywords
transposase
seq
tcbuster transposase
amino acid
mutant tcbuster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527427A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038410 external-priority patent/WO2019246486A2/en
Publication of JP2021527427A publication Critical patent/JP2021527427A/ja
Publication of JPWO2019246486A5 publication Critical patent/JPWO2019246486A5/ja
Priority to JP2024001350A priority Critical patent/JP2024041866A/ja
Pending legal-status Critical Current

Links

JP2020570813A 2018-06-21 2019-06-21 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 Pending JP2021527427A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001350A JP2024041866A (ja) 2018-06-21 2024-01-09 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688278P 2018-06-21 2018-06-21
US62/688,278 2018-06-21
PCT/US2019/038410 WO2019246486A2 (en) 2018-06-21 2019-06-21 ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001350A Division JP2024041866A (ja) 2018-06-21 2024-01-09 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法

Publications (2)

Publication Number Publication Date
JP2021527427A JP2021527427A (ja) 2021-10-14
JPWO2019246486A5 true JPWO2019246486A5 (ru) 2023-08-02

Family

ID=67211911

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570813A Pending JP2021527427A (ja) 2018-06-21 2019-06-21 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法
JP2024001350A Pending JP2024041866A (ja) 2018-06-21 2024-01-09 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001350A Pending JP2024041866A (ja) 2018-06-21 2024-01-09 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法

Country Status (7)

Country Link
US (1) US11760983B2 (ru)
EP (1) EP3810764A2 (ru)
JP (2) JP2021527427A (ru)
CN (1) CN112543808A (ru)
AU (1) AU2019288669A1 (ru)
CA (1) CA3104288A1 (ru)
WO (1) WO2019246486A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230272355A1 (en) * 2020-06-05 2023-08-31 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY MEMBER SPIN TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2023004366A1 (en) 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Transposon-based modulation of gba1 and related compositions and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431246A1 (en) 2000-12-05 2002-06-13 Wisconsin Alumni Research Foundation Double transposition methods for manipulating nucleic acids
US7064246B2 (en) 2001-05-01 2006-06-20 Macrae Amy F Use of transposable elements for altering gene expression
US7262056B2 (en) 2001-11-08 2007-08-28 Mirus Bio Corporation Enhancing intermolecular integration of nucleic acids using integrator complexes
EP1458875A2 (de) 2001-12-20 2004-09-22 Sungene GmbH & Co. KGaA Verfahren zur transformation von pflanzlichen plastiden
WO2004070042A1 (en) 2003-02-10 2004-08-19 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Transposon-based targeting system
WO2004069994A2 (en) 2003-02-10 2004-08-19 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Transposon-based targeting system
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US20060252140A1 (en) 2005-04-29 2006-11-09 Yant Stephen R Development of a transposon system for site-specific DNA integration in mammalian cells
US9175295B2 (en) 2005-07-05 2015-11-03 The Chemo-Sero-Therapeutic Research Institute Modified transposon vector and its use
CA2692501C (en) 2007-07-04 2017-10-10 Max-Delbrueck-Centrum Fuer Molekulare Medizin Hyperactive variants of the transposase protein of the transposon system sleeping beauty
US8524979B2 (en) 2008-04-14 2013-09-03 National Taiwan University Termination of transgene expression via transposon-mediated break
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8399643B2 (en) 2009-02-26 2013-03-19 Transposagen Biopharmaceuticals, Inc. Nucleic acids encoding hyperactive PiggyBac transposases
EP2441831B9 (en) 2009-06-11 2019-03-06 Inter-University Research Institute Corporation Research Organization of Information and Systems Process for production of protein
CN110452882A (zh) 2010-12-09 2019-11-15 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途
US20130017978A1 (en) 2011-07-11 2013-01-17 Finnzymes Oy Methods and transposon nucleic acids for generating a dna library
JP2014533928A (ja) 2011-09-16 2014-12-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を処置するためのｒｎａ操作ｔ細胞
DK3141259T3 (da) 2012-03-15 2019-09-30 Cellectis Repeat-variable direster til targeting af nukleotider
SI2692865T1 (sl) 2012-07-30 2015-03-31 Nbe-Therapeutics Llc Technology Parc Basel S transpozicijo posredovana identifikacija specifičnih vezavnih ali funkcionalnih proteinov
ES2717175T3 (es) 2013-02-01 2019-06-19 Selexis Sa Expresión mejorada de transgenes y procesamiento
JP6463577B2 (ja) 2013-05-14 2019-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
CA2943296C (en) 2014-03-21 2022-10-18 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
CN103981204B (zh) 2014-03-24 2016-05-04 上海海洋大学 一种有活性的金鱼Tgf2转座子重组转座酶蛋白的表达方法
WO2015157579A2 (en) 2014-04-09 2015-10-15 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
JP2017518082A (ja) 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用
EP3201343B1 (en) 2014-09-29 2022-03-23 The Jackson Laboratory High efficiency, high throughput generation of genetically modified mammals by electroporation
EP3018200A1 (en) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
US20180080051A1 (en) 2015-03-31 2018-03-22 Exeligen Scientific, Inc. Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism
EP3283635B1 (en) 2015-04-13 2022-07-06 Maxcyte, Inc. Methods and compositions for modifying genomic dna
WO2016191618A1 (en) 2015-05-27 2016-12-01 Jianbiao Zheng Methods of inserting molecular barcodes
EP3929286A1 (en) 2015-06-17 2021-12-29 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
EP3350335B1 (en) 2015-09-16 2019-11-27 T-CURX GmbH Improved transposon system for gene delivery
CN108601849A (zh) 2015-09-22 2018-09-28 尤利乌斯·马克西米利安维尔茨堡大学 一种在淋巴细胞中高水平的和稳定的基因转移的方法
CN105154473B (zh) 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
CN108138171B (zh) 2015-10-08 2022-05-13 国立大学法人名古屋大学 表达嵌合抗原受体的基因修饰t细胞的制备方法
KR102249982B1 (ko) 2015-12-14 2021-05-11 게놈프론티어 테라퓨틱스 인코포레이티드 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도
WO2017123758A1 (en) 2016-01-12 2017-07-20 Seqwell, Inc. Compositions and methods for sequencing nucleic acids
RU2018128464A (ru) 2016-02-25 2020-03-25 Селл Медика Свитзерленд Аг Связывающие элементы против pd-l1
EP3420090A1 (en) 2016-02-26 2019-01-02 Poseida Therapeutics, Inc. Transposon system and methods of use
EP3219800A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
WO2017171631A1 (en) 2016-03-31 2017-10-05 Lion Tcr Pte. Ltd. Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)
EP3452082A1 (en) 2016-05-04 2019-03-13 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
CN107523548A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的t细胞及其用途
CN107523549A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达激活型抗体的car‑t细胞及其用途
CN107523545A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
CN107523547A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
WO2018015936A2 (en) 2016-07-21 2018-01-25 Maxcyte, Inc. Methods and compositions for modifying genomic dna
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
US11414680B2 (en) 2016-08-30 2022-08-16 Kyushu University National University Corporation Method for inserting desired DNA fragment into site located adjacent to binding domain of DNA-binding protein
WO2018057779A1 (en) 2016-09-23 2018-03-29 Jianbiao Zheng Compositions of synthetic transposons and methods of use thereof
IL287286B (en) 2016-09-30 2022-09-01 Poseida Therapeutics Inc Differentiated stem cell memory t cells, methods for their preparation and methods for using them
WO2018102612A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
WO2018112415A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
IL310711A (en) 2017-01-10 2024-04-01 Intrexon Corp Modulation of expression of polypeptides through a new system for changing gene expression
WO2018140644A1 (en) 2017-01-25 2018-08-02 Musc Foundation For Research Development Modified t cells and uses thereof

Similar Documents

Publication Publication Date Title
CN110891420B (zh) Cas转基因小鼠胚胎干细胞和小鼠及其应用
KR102647714B1 (ko) CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
US12037611B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
JP2020501612A5 (ru)
KR20210021473A (ko) 푸소솜 조성물 및 그의 용도
WO2010105277A1 (en) Compositions and methods for the delivery of biologically active rnas
EP3810764A2 (en) Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
JP2019503653A (ja) トランスポゾン系、それを含むキット及びそれらの使用
AU2012358181A1 (en) Compositions and methods for the delivery of biologically active RNAs
CN114164231A (zh) 对细胞中的靶位点进行基因编辑的方法
JPWO2019246486A5 (ru)
EP3924497A1 (en) Site specific recombinase integrase variants and uses thereof in gene editing in eukaryotic cells
WO2020186237A1 (en) Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof
WO2024041653A1 (zh) 一种CRISPR-Cas13系统及其应用
WO2023085433A1 (ja) ヒト細胞内でヒト人工染色体ベクターを作製する方法
WO2024131786A1 (zh) 一种在基因组插入大片段dna的系统
WO2024040202A1 (en) Fusion proteins and uses thereof for precision editing
EP4141119A2 (en) Hairpin loop ended self-complementary double-stranded covalently closed linear dna vector, manufacturing system and process, and uses of said resulting dna vector
US20230272355A1 (en) ENHANCED hAT FAMILY MEMBER SPIN TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
WO2023196818A1 (en) Genetic complementation compositions and methods
KR20240117571A (ko) 돌연변이 마이오실린 질환 모델 및 이의 용도
Eghbalsaied et al. A versatile bulk electrotransfection protocol for mouse embryonic fibroblast and iPS cells
CN117355607A (zh) 非病毒同源性介导的末端连接
Long Development of strategies to enhance the contribution of hematopoietic cells to skeletal muscle repair